Abstract Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety. Our report suggests that Remdesivir is well tolerated and potentially safe among hospitalized patients with severe COVID‐19 infection with the background of advanced kidney diseases where benefits outweigh potential risks.
All Keywords
【저자키워드】 COVID‐19, SARS‐CoV‐2, Remdesivir, chronic kidney diseases (CKD), 【초록키워드】 Treatment, Antiviral, FDA, COVID‐19, management, Kidney disease, metabolite, Evidence, Safe, toxicities, COVID‐19 infection, renal, benefit, severe renal impairment, patient group, hospitalized patient, restrict, accumulate, receive, 【제목키워드】 Pneumonia, COVID‐19, kidney, Patient,
【저자키워드】 COVID‐19, SARS‐CoV‐2, Remdesivir, chronic kidney diseases (CKD), 【초록키워드】 Treatment, Antiviral, FDA, COVID‐19, management, Kidney disease, metabolite, Evidence, Safe, toxicities, COVID‐19 infection, renal, benefit, severe renal impairment, patient group, hospitalized patient, restrict, accumulate, receive, 【제목키워드】 Pneumonia, COVID‐19, kidney, Patient,